Cystic Fibrosis trials in Canada: Trial Insights

Filters: Condition: Cystic Fibrosis Country / region: Canada Clear all

177 trials match Source: ClinicalTrials.gov registrations

Top lead sponsors
Category	Trials
Vertex Pharmaceuticals Incorporated	56
The Hospital for Sick Children	16
University of British Columbia	15
Institut de Recherches Cliniques de Montreal	7
Gilead Sciences	5
Unity Health Toronto	5
PTC Therapeutics	4
CF Therapeutics Development Network Coordinating Center	3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	3
Novartis Pharmaceuticals	3

Trials

Showing 26 to 50 of 177. Each trial links to its page on Pharma Observatory.

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes NCT04545515Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2021
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years NCT04537793Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2020
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders NCT02748798Phase 1TerminatedThunder Bay Regional Health Research InstituteStarted 2020
Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis NCT04496921Not applicableWithdrawnInstitut de Recherches Cliniques de MontrealStarted 2020
Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF NCT04553419Phase 3Unknown statusUniversity of British ColumbiaStarted 2020
Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis NCT04279769Phase 1CompletedCalithera Biosciences, IncStarted 2020
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes NCT04353817Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2020
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation NCT04235140Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2020
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older NCT04183790Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2020
Hyperpolarized Imaging for New Treatments NCT04259970Phase 4CompletedChildren's Hospital Medical Center, CincinnatiStarted 2020
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 NCT03969888Phase 2CompletedAbbVieStarted 2019
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy NCT04058366Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2019
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele NCT04135495Phase 2CompletedEloxx Pharmaceuticals, Inc.Started 2019
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1 NCT04059094Phase 2TerminatedBoehringer IngelheimStarted 2019
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) NCT04058353Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2019
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy NCT04043806Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2019
Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis NCT03903913Phase 2Unknown statusSolAeroMed Inc.Started 2019
Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath) NCT04735952ObservationalUnknown statusUniversity of British ColumbiaStarted 2019
The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis NCT03710538Not applicableCompletedInstitut de Recherches Cliniques de MontrealStarted 2019
Effects of Automated Oxygen Titration Alone or With High Flow Nasal Therapy on Dyspnea and Exercise Tolerance NCT05267418Not applicableTerminatedLaval UniversityStarted 2019
Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults NCT03265288Phase 2CompletedLaurent Pharmaceuticals Inc.Started 2018
Measures of Respiratory Health Registry NCT05501587ObservationalRecruitingUniversity of British ColumbiaStarted 2018
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy NCT03525574Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2018
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age NCT03691779Phase 3CompletedVertex Pharmaceuticals IncorporatedStarted 2018
Intestinal Inflammation in CF Patients NCT04392544ObservationalActive, not recruitingThe Hospital for Sick ChildrenStarted 2018

77 more trials match. See them on Pharma Observatory

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age NCT05882357Enrollment change70 to 67October 17, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory